查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612197

抗瘧疾藥市場：按藥物類別、按藥物類型、按給藥途徑、按瘧疾類型、按配銷通路、按最終用戶 - 2025-2030 年全球預測

Antimalarial Drugs Market by Drug Class (Antifolate compounds, Artemisinin compounds, Aryl aminoalcohol compounds), Drug Type (Branded, Generic), Route of Administration, Malaria Type, Distribution Channel, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗瘧疾藥市值為16.7億美元，預計2024年將達到17.6億美元，複合年成長率為5.88%，預計2030年將達25億美元。

抗瘧疾藥的範圍是用於預防和治療瘧疾的開發、分銷和應用，瘧疾是一種由寄生蟲引起的疾病，主要透過受感染的蚊子叮咬傳播。瘧疾的持續流行證明了對這些藥物的需求，特別是在熱帶和亞熱帶地區，瘧疾對這些地區的健康構成了重大挑戰。抗瘧疾藥不僅可用於疾病流行地區，還可作為前往這些地區的人們的旅行藥物。最終的使用範圍將包括公共衛生活動、醫院、診所和藥房的店面銷售，以滿足流行地區居民和遊客的需求。

主要市場統計
基準年[2023] 16.7億美元
預計年份 [2024] 17.6億美元
預測年份 [2030] 25億美元
複合年成長率（%） 5.88%

根據市場洞察，抗瘧疾藥的需求受到全球瘧疾流行、全球衛生措施以及持續的抗藥性研究工作等因素的影響。在政府措施以及製藥公司與衛生當局之間的合作夥伴關係的推動下，對開發下一代治療方法（包括疫苗和新藥物配方）的投資也在增加。將人工智慧等新技術融入藥物發現、擴大農村地區的使用範圍以及開發兒童友善配方等方面存在潛在機會。然而，瘧疾原蟲抗藥性菌株的出現、藥物開發高成本以及監管障礙等挑戰帶來了限制。這些障礙可能會減緩市場成長並需要持續的研究工作。

創新可能會在對抗抗藥性細菌的聯合治療、開發快速診斷測試以指南個人化治療以及利用生物技術開發疫苗等領域取得進展。儘管市場競爭依然激烈，但新參與企業仍有空間願意投資研發和合作。了解當地市場動態並使您的產品線多樣化以滿足當地需求可以提高您的市場佔有率。總之，要抓住抗瘧疾藥市場的成長機會，必須對抗藥性趨勢保持警惕，利用技術進步並應對獲取挑戰。

市場動態：揭示快速發展的抗瘧疾藥市場的關鍵市場洞察

供需的動態交互作用正在改變抗瘧疾藥市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球瘧疾發病率上升（特別是在熱帶和亞熱帶地區）
    • 世界衛生組織加大對消除瘧疾計畫的支持
  • 市場限制因素
    • 抗藥性瘧疾菌株的出現
  • 市場機會
    • 政府與製藥公司之間的合作關係旨在擴大抗瘧疾藥的傳播
    • 瘧疾治療的發展和診斷測試的研發
  • 市場問題
    • 劑量不正確、嚴格遵守規定、藥品品質差等問題

波特五力：駕馭抗瘧疾藥市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗瘧疾藥市場的外部影響

外部宏觀環境因素在塑造抗瘧疾藥市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解抗瘧疾藥市場的競爭格局

抗瘧疾藥市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：抗瘧疾藥市場供應商績效評估

FPNV定位矩陣是評估抗瘧疾藥市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製抗瘧疾藥市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，抗瘧疾藥市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 瘧疾的發生率在全世界範圍內不斷增加，特別是在熱帶和亞熱帶地區。
      • 世界衛生組織加大對消除瘧疾計畫的支持
    • 抑制因素
      • 抗藥性瘧疾菌株的出現
    • 機會
      • 政府與藥廠合作促進抗瘧疾藥普及
      • 瘧疾藥物開發與診斷測試的研究與開發
    • 任務
      • 與劑量錯誤、嚴格遵守和藥品品質不佳有關的問題
  • 市場區隔分析
    • 藥物類別：青蒿素化合物的功效擴大了用途
    • 瘧疾類型：瘧疾原蟲盛行率增加
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章抗瘧疾藥市場：依藥物類別

  • 介紹
  • 抗葉酸化合物
  • 青蒿素化合物
  • 胺基醇化合物
  • 內過氧化物
  • 喹啉甲醇
  • 四環黴素

第7章抗瘧疾藥市場：按藥物類型

  • 介紹
  • 品牌
  • 非專利的

抗瘧疾藥市場：依給藥途徑

  • 介紹
  • 靜脈
  • 口服

第9章抗瘧疾藥市場：依瘧疾類型

  • 介紹
  • Plasmodium Falciparum
  • Plasmodium Knowlesi
  • Plasmodium Malariae
  • Plasmodium Ovale
  • Plasmodium Vivax

第10章抗瘧疾藥市場：依通路分類

  • 介紹
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章抗瘧疾藥市場：依最終用戶分類

  • 介紹
  • 醫院
  • 專科診所

第12章美洲抗瘧疾藥市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太抗瘧疾藥市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲抗瘧疾藥市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 肯亞製藥公司成為非洲第一家獲得世界衛生組織核准用於瘧疾治療的製藥公司
    • 復星醫藥與國際金融公司合作改善非洲優質藥品的獲取
    • 復星醫藥研發青蒿素類創新抗瘧疾藥
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Alkem Laboratories
  • Alliance Pharma
  • Alvizia Health Care
  • Bayer AG
  • Cipla Inc.
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Ipca Laboratories Ltd.
  • Lincoln Pharmaceuticals
  • Lupin Limited
  • Merck KGaA
  • Mylan
  • Novartis AG
  • Pfizer Inc.
  • Sanofi Group
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceuticals Industries Ltd.
  • Zydus Group
  • Zydus Lifesciences Ltd.
Product Code: MRR-F97DD5A7DAEF

The Antimalarial Drugs Market was valued at USD 1.67 billion in 2023, expected to reach USD 1.76 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 2.50 billion by 2030.

The scope of antimalarial drugs encompasses their development, distribution, and application primarily for the prevention and treatment of malaria, a disease caused by parasites transmitted through infected mosquito bites. The necessity for these drugs is underscored by malaria's persistent prevalence, particularly in tropical and subtropical regions, where it poses significant health challenges. Antimalarial drugs find application not only in disease-endemic regions but also in travel medicine for individuals visiting such areas. Ultimately, the end-use scope includes public health initiatives, hospitals, clinics, and over-the-counter availability in pharmacies, catering to both the endemic population and travelers.

KEY MARKET STATISTICS
Base Year [2023] USD 1.67 billion
Estimated Year [2024] USD 1.76 billion
Forecast Year [2030] USD 2.50 billion
CAGR (%) 5.88%

Market insights reveal that the demand for antimalarial drugs is influenced by factors such as the global incidence rate of malaria, international health policies, and ongoing research efforts into drug resistance. There's also an increased investment in developing next-generation therapies, including vaccines and novel drug formulations, driven by government initiatives and collaborations between pharmaceutical companies and health organizations. Potential opportunities lie in the integration of new technologies such as AI in drug discovery, expanding access to rural areas, and developing pediatric-friendly formulations. However, limitations arise from challenges such as the emergence of drug-resistant strains of malaria parasites, high costs of drug development, and regulatory hurdles. These impediments may slow market growth and require sustained research efforts.

Innovation can thrive in areas like combination therapies to tackle resistance, development of rapid diagnostic tests that can guide personalized treatment, and leveraging biotechnology for vaccine development. The market remains competitive but offers room for new entrants willing to invest in R&D and collaborations. Understanding regional market dynamics and diversifying product lines to align with specific local needs can enhance market presence. In summary, maintaining vigilance on resistance trends, capitalizing on technological advancements, and addressing access challenges are crucial for seizing growth opportunities in the antimalarial drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antimalarial Drugs Market

The Antimalarial Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence rates of malaria globally, particularly in tropical and subtropical regions
    • Increasing support from global health organizations for malaria eradication programs
  • Market Restraints
    • Emergence of drug-resistant malaria strains
  • Market Opportunities
    • Collaborations between governments and pharmaceutical companies for increasing penetration of anti-malaria drugs
    • Research and development in drug development and diagnostic tests for malaria
  • Market Challenges
    • Issues related to incorrect dosing, strict compliance, and poor drug quality

Porter's Five Forces: A Strategic Tool for Navigating the Antimalarial Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antimalarial Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antimalarial Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antimalarial Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antimalarial Drugs Market

A detailed market share analysis in the Antimalarial Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antimalarial Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antimalarial Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antimalarial Drugs Market

A strategic analysis of the Antimalarial Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antimalarial Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories, Alliance Pharma, Alvizia Health Care, Bayer AG, Cipla Inc., Dr. Reddy's Laboratories, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Glenmark Pharmaceuticals, Hikma Pharmaceuticals PLC, Ipca Laboratories Ltd., Lincoln Pharmaceuticals, Lupin Limited, Merck KGaA, Mylan, Novartis AG, Pfizer Inc., Sanofi Group, Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company, Teva Pharmaceuticals Industries Ltd., Zydus Group, and Zydus Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Antimalarial Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Antifolate compounds, Artemisinin compounds, Aryl aminoalcohol compounds, Endoperoxides, Quinoline Methanols, and Tetracyclines.
  • Based on Drug Type, market is studied across Branded and Generic.
  • Based on Route of Administration, market is studied across Intravenous and Oral.
  • Based on Malaria Type, market is studied across Plasmodium Falciparum, Plasmodium Knowlesi, Plasmodium Malariae, Plasmodium Ovale, and Plasmodium Vivax.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on End User, market is studied across Hospitals and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence rates of malaria globally, particularly in tropical and subtropical regions
      • 5.1.1.2. Increasing support from global health organizations for malaria eradication programs
    • 5.1.2. Restraints
      • 5.1.2.1. Emergence of drug-resistant malaria strains
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborations between governments and pharmaceutical companies for increasing penetration of anti-malaria drugs
      • 5.1.3.2. Research and development in drug development and diagnostic tests for malaria
    • 5.1.4. Challenges
      • 5.1.4.1. Issues related to incorrect dosing, strict compliance, and poor drug quality
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Widening use of artemisinin compounds owing to its effective results
    • 5.2.2. Malaria Type: Increasing prevalence of plasmodium falciparum
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antimalarial Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Antifolate compounds
  • 6.3. Artemisinin compounds
  • 6.4. Aryl aminoalcohol compounds
  • 6.5. Endoperoxides
  • 6.6. Quinoline Methanols
  • 6.7. Tetracyclines

7. Antimalarial Drugs Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Branded
  • 7.3. Generic

8. Antimalarial Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral

9. Antimalarial Drugs Market, by Malaria Type

  • 9.1. Introduction
  • 9.2. Plasmodium Falciparum
  • 9.3. Plasmodium Knowlesi
  • 9.4. Plasmodium Malariae
  • 9.5. Plasmodium Ovale
  • 9.6. Plasmodium Vivax

10. Antimalarial Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Antimalarial Drugs Market, by End User

  • 11.1. Introduction
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Americas Antimalarial Drugs Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Antimalarial Drugs Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Antimalarial Drugs Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Kenya Manufacturer Is First In Africa to Get WHO Approval For Malaria Drug
    • 15.3.2. Fosun Pharma and IFC Partner to Improve Access to High Quality Medicines in Africa
    • 15.3.3. Fosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alkem Laboratories
  • 3. Alliance Pharma
  • 4. Alvizia Health Care
  • 5. Bayer AG
  • 6. Cipla Inc.
  • 7. Dr. Reddy's Laboratories
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. GlaxoSmithKline plc
  • 10. Glenmark Pharmaceuticals
  • 11. Hikma Pharmaceuticals PLC
  • 12. Ipca Laboratories Ltd.
  • 13. Lincoln Pharmaceuticals
  • 14. Lupin Limited
  • 15. Merck KGaA
  • 16. Mylan
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Sanofi Group
  • 20. Strides Pharma Science Limited
  • 21. Sun Pharmaceutical Industries Ltd.
  • 22. Takeda Pharmaceutical Company
  • 23. Teva Pharmaceuticals Industries Ltd.
  • 24. Zydus Group
  • 25. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTIMALARIAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIMALARIAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ANTIMALARIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. ANTIMALARIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIMALARIAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIMALARIAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ANTIFOLATE COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARYL AMINOALCOHOL COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ENDOPEROXIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUINOLINE METHANOLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM FALCIPARUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM KNOWLESI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM MALARIAE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM OVALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM VIVAX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 283. ANTIMALARIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. ANTIMALARIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023